Filter Results


Study status

(for at least one location)



Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 48 for multiple myeloma

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Response Adapted Combination Therapy Approaches for High-Risk Multiple Myeloma

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  2. Immune Monitoring and Immunotherapy in Myeloma

    Rochester, MN

  3. A Study to Evaluate the Effectiveness and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma

    Scottsdale/Phoenix, AZ

  4. A Study to Evaluate TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  6. Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

    Rochester, MN

  7. Study to Evaluate Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  8. Belantamab, Lenalidomide, and Daratumumab for Newly-diagnosed Multiple Myeloma

    Rochester, MN

  9. A Study to Evaluate the Safety, Tolerance and Anti-tumor Activity of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Non-Hodgkin Lymphoma

    Rochester, MN

  10. Iberdomide in Combination with Daratumumab, Bortezomib, and Dexamethasone in Patients with Newly-diagnosed Multiple Myeloma (IDEAL)

    Rochester, MN


Mayo Clinic Footer